Indonesia Patent System

Indonesia is a major global manufacturing hub — the world's 4th most populous country and Southeast Asia's largest economy. Foreign companies with significant manufacturing operations in Indonesia include: Electronics: Samsung (Cikarang — TV, home appliances; largest Samsung TV manufacturing plant in Southeast Asia); LG Electronics (Tangerang); Panasonic (Batam); Sharp (Karawang). These companies' Indonesian manufacturing activities are covered by global patent portfolios filed primarily in their home countries (Korea, Japan) and via PCT for major markets, not specifically at DGIP. However, process innovations developed in Indonesian factories may be patentable and should be captured in Indonesian employee inventor agreements under Indonesian law. Automotive: Toyota Motor Indonesia (Karawang + Sunter — Kijang Innova, Corolla, Veloz manufacturing); Honda Prospect Motor (Karawang — HR-V, BR-V, Brio Satya); Daihatsu (Karawang — Indonesia is Daihatsu's largest market globally; Toyota-Daihatsu joint ventures); Astra International (Indonesia's largest automotive distributor, also has manufacturing JVs). Indonesian automotive patents: Indonesia-specific automotive patents exist primarily for locally-adapted vehicles (LCGCs — Low Cost Green Cars, an Indonesian government program mandating local content). Local vehicle adaptations for Indonesian roads, climate, and fuel specifications generate some national patent filings at DGIP. Commodities: Indonesia is the world's largest palm oil producer. Palm oil processing technology patents (extraction, fractionation, refinery processes) are filed at DGIP by Indonesian companies (Wilmar, Sinar Mas, Golden Agri-Resources) and by international oleochemical companies. Nickel, coal, and bauxite mining process patents are also filed by domestic and international mining companies.

Indonesia has one of the world's fastest-growing digital economies — by app usage, Indonesia ranks among the top globally in social media, messaging, and e-commerce app penetration. Key Indonesian technology companies with IP activity: GoTo Group (Jakarta — merger of Gojek and Tokopedia; Southeast Asia's largest tech company by valuation; holds patents in ride-hailing algorithms, on-demand logistics routing, digital payments, and e-commerce matching; files primarily via PCT and in Singapore as regional patent hub; DGIP national patent filings are secondary); Bank Jago, OVO, GoPay, Dana — fintech patent activity focused primarily in Singapore and regional hubs for international protection. DGIP software patent practice: Indonesian Patent Law No. 13/2016 excludes certain abstract computer programs from patentability (consistent with TRIPS Art. 27(2) allowances). However, computer-implemented inventions with a technical character — software producing a tangible technical effect — can be patented in Indonesia. DGIP follows examination guidelines aligned with international practice but with limited examiner resources in software-heavy patent categories, leading to long examination timelines. Indonesian technology companies' strategy: most file primarily at the USPTO and via PCT/EPO for international markets, with Indonesian national phase entry selectively for products with significant domestic market exposure. The Indonesian digital economy ($77 billion+ GMV by some estimates) makes domestic patent protection increasingly important as competition intensifies between regional players.

ASPEC (ASEAN Patent Examination Cooperation) is a work-sharing program among the patent offices of ASEAN member states — Indonesia (DGIP), Singapore (IPOS), Malaysia (MyIPO), Thailand (DIP), the Philippines (IPOPHL), Vietnam (NOIP), Brunei, Cambodia, Laos, and Myanmar. Under ASPEC: (1) An applicant who has obtained search and examination results from one ASEAN patent office can submit those results to another ASEAN patent office to use as a basis for examination of the same application. This is designed to avoid duplicative examination work across ASEAN national offices; (2) For Indonesia specifically: applicants who first receive positive examination results from Singapore's IPOS — which is known for efficient, high-quality examination and is the regional IP hub — can submit those results to DGIP under ASPEC. DGIP can then take the IPOS examination results into account, potentially accelerating Indonesian examination without requiring full re-examination from scratch; (3) ASPEC is not binding: each participating office retains its own examination standards. DGIP may agree with the IPOS examination or may conduct its own review and reach different conclusions. In practice, positive results from IPOS tend to carry significant weight with DGIP; (4) How to use ASPEC for Indonesia: file in Singapore first (or as part of a PCT application where IPOS is the International Searching Authority/International Preliminary Examining Authority), obtain positive results, then enter the Indonesian national phase at DGIP and submit the IPOS results through the ASPEC mechanism. This works best for technology areas where DGIP and IPOS apply similar patentability standards; (5) ASPEC and PCT: applicants using PCT can designate IPOS as ISA/IPEA to maximize the work-sharing benefit for subsequent ASEAN national phases, including Indonesia.

Indonesia has issued government compulsory licenses for pharmaceutical patents primarily to address the HIV/AIDS epidemic at a scale that was unaffordable using patented antiretroviral (ARV) drugs. The key events: (1) 2004 Presidential Decree No. 83: President Megawati issued this decree authorizing compulsory licenses for seven ARV drugs — lamivudine, nevirapine, efavirenz, zidovudine, didanosine, stavudine, and lopinavir/ritonavir. These drugs were patented by GlaxoSmithKline (lamivudine, zidovudine, didanosine/stavudine), Boehringer Ingelheim (nevirapine), Merck/Gilead (efavirenz), and Abbott Laboratories (lopinavir/ritonavir). At prevailing branded drug prices, treating Indonesia's HIV-positive population at the scale required was fiscally impossible for the public health system. Compulsory licensing allowed PT Kimia Farma and Indofarma (state-owned pharma manufacturers) to produce generics at dramatically lower cost; (2) TRIPS legal basis: Indonesia's compulsory licenses were consistent with TRIPS Art. 31 and the 2001 Doha Declaration on TRIPS and Public Health, which confirmed that TRIPS allows WTO members to grant compulsory licenses and each member is free to determine what constitutes a national emergency. HIV/AIDS epidemics have been recognized as public health emergencies; (3) 2012 extension Decree: a second Presidential Decree in 2012 extended and updated the compulsory license for several ARV drugs. This multi-decree pattern is unusual — most countries issue at most one compulsory license for a given situation. Indonesia's sustained commitment to compulsory licensing for HIV/AIDS reflects continued public health need and political will; (4) Remuneration: patent holders were entitled to 'adequate remuneration' under TRIPS Art. 31(h). Indonesia paid royalties to patent holders, typically at rates substantially below standard commercial licensing rates; (5) International reaction: originator pharmaceutical companies protested diplomatically but did not mount successful legal challenges under TRIPS dispute settlement. No formal WTO dispute settlement case was filed against Indonesia over these compulsory licenses.

Article 20 of Indonesian Patent Law No. 13 of 2016 requires patent holders to 'exploit' (work) their patents in Indonesia within 36 months of the patent grant date. The working requirement has several dimensions: (1) What counts as working: the law requires that the patented invention be made or used in Indonesia, or that products incorporating the invention be manufactured in Indonesia. Mere importation of patented products into Indonesia without local manufacturing is generally considered INSUFFICIENT to satisfy the working requirement. This is more stringent than many countries where importation suffices to satisfy working requirements; (2) Consequences of non-working: if a patent is not worked in Indonesia within 36 months, any third party can request a compulsory license from DGIP to work the invention in Indonesia. DGIP can grant the compulsory license with compensation to the patent holder; (3) Exception — importation: the law provides that if local manufacture is not feasible (e.g., the technology requires specialized equipment not available in Indonesia), the patent holder may satisfy the working requirement through importation combined with other measures demonstrating commitment to local exploitation (local distribution, service network, etc.). This exception is evaluated case-by-case; (4) Practical implications for patent holders: companies selling patented products in Indonesia without manufacturing locally — particularly in pharmaceuticals, consumer electronics, and industrial equipment — face a working requirement risk. Strategies to address this include: establishing local licensing arrangements with Indonesian manufacturers; creating local assembly operations (even if not full manufacture); documenting why local manufacture is infeasible and relying on the importation exception; or accepting the risk that the working requirement may not be enforced strictly in practice (DGIP's compulsory license mechanism has limited resources for proactive enforcement); (5) 2016 reform: the 2016 Patent Law clarified the working requirement compared to the 2001 Law, but debate continues about what constitutes sufficient local exploitation.

An Indonesian simple patent (paten sederhana) under Articles 3 and 22 of Patent Law No. 13 of 2016 is Indonesia's equivalent of a utility model — a shorter-term, lower-inventive-step patent option for simpler innovations. Key features: (1) Term: 10 years from filing date (compared to 20 years for a regular patent); (2) Inventive step standard: the inventive step requirement for simple patents is lower than for regular patents. A simple patent covers innovations that have 'practical value' and are novel — meaning straightforward improvements to tools, products, or devices that don't rise to the full inventive step standard for regular patents; (3) What can be protected: simple patents cover devices, products, compositions, and working methods (methods of using). Unlike some other countries' utility models, Indonesian simple patents can also protect methods and processes (not just physical products); (4) Examination: simple patents go through substantive examination at DGIP (novelty and practical value), but the examination scope is lighter than for regular patents. Simple patents are typically granted faster — 1–2 years vs. 3–6 years for regular patents; (5) No SPC for simple patents: supplementary protection certificate (SPC) mechanisms require a regular patent as the base; simple patents do not qualify; (6) When to use: simple patents are valuable for Indonesian SMEs, local manufacturers, and artisans who make incremental improvements to tools, agricultural equipment, construction materials, household products, or food processing equipment. The lower cost, faster prosecution, and lower inventive step bar make simple patents accessible. Foreign applicants can also file simple patents at DGIP via PCT or direct national filing; (7) Cannot coexist: you cannot have both a simple patent and a regular patent on the same invention in Indonesia simultaneously.

For global companies, Indonesian patent strategy should be driven by commercial priorities in Indonesia's 275+ million consumer market, Southeast Asia's largest economy: (1) PCT is the standard route: file PCT → enter Indonesian national phase within 31 months from priority date. This gives maximum time to assess the commercial value of the Indonesian market before committing to DGIP prosecution costs. Indonesian national phase fees are relatively modest; (2) ASPEC leverage: after obtaining positive search/examination results from a reliable ASEAN patent office (ideally IPOS Singapore), use the ASPEC mechanism for DGIP examination. This can significantly reduce DGIP examination time; (3) Simple patents for straightforward innovations: consider filing a simple patent application in parallel with a regular patent application, or as an alternative, for incremental innovations that may not meet the full inventive step standard. Simple patents grant faster and provide 10 years of protection — sufficient for many product life cycles; (4) Pharmaceutical companies: be aware of Indonesia's active compulsory licensing history and local working requirement. Voluntary licensing to a local manufacturer (e.g., PT Kimia Farma, Kalbe Farma) may be preferable to defending against compulsory license applications. Pharmaceutical patent linkage with BPOM (Indonesia's drug regulator) is informal — monitor BPOM generic registrations independently; (5) Technology companies: software-intensive innovations require careful claim drafting to demonstrate technical character for Indonesian prosecution. File claims with hardware/system integration elements. Indonesia's digital economy growth makes local digital market protection increasingly valuable; (6) Manufacturing sector: document employee inventor agreements carefully under Indonesian law. Process innovations developed in Indonesian factories should be captured and evaluated for patentability — simple patents may provide quick, cost-effective protection for manufacturing process improvements.